Gezond ouder worden – Een Euregionale opportuniteit (Q4300679): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
| Property / contained in NUTS | |||
| Property / contained in NUTS: Zuid-Limburg / rank | |||
Normal rank | |||
Revision as of 20:07, 16 June 2022
Project Q4300679 in Germany, Belgium, Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gezond ouder worden – Een Euregionale opportuniteit |
Project Q4300679 in Germany, Belgium, Netherlands |
Statements
2,376,070.61 Euro
0 references
4,752,192.75 Euro
0 references
50.0 percent
0 references
1 January 2016
0 references
30 June 2021
0 references
Hasselt University, Biomedical Research Institute
0 references
50°28'24.96"N, 5°22'56.68"E
0 references
50°55'42.49"N, 5°23'19.57"E
0 references
50°39'12.96"N, 5°33'47.81"E
0 references
50°34'23.41"N, 5°34'2.35"E
0 references
50°55'48.94"N, 5°23'34.73"E
0 references
50°50'0.10"N, 5°42'57.85"E
0 references
50°56'51.18"N, 5°13'52.79"E
0 references
50°46'36.66"N, 6°2'36.20"E
0 references
50°50'3.30"N, 5°42'48.96"E
0 references
50°49'54.91"N, 5°42'55.37"E
0 references
50°55'54.80"N, 5°23'42.76"E
0 references
Ageing – a Euregional challenge and opportunity: Even more than other Western European regions, the EMR region has a progressively ageing population. With the expanding numbers of elderly comes an increase in age-related chronic diseases such as rheumatoid arthritis (RA), asthma, chronic obstructive pulmonary disease (COPD), neurodegenerative diseases (e.g. MS), and cardiovascular diseases (CVD) [1],[2],[3], especially when combined with a unhealthy lifestyle, as is the case for the EMR 4,5. This coincides with soaring health costs not to mention loss of quality of life. Hence, people live longer but not necessarily better. Therefore, the EMR can be viewed as a living lab, where ageing-related health issues will manifest even sooner and at a larger scale than in other regions. The ample presence of private and academic institutions with complementary expert focus on health, chronic diseases, and cutting-edge medical technology could provide, when linked to the EMR living lab, offers unprecedented socio-economical opportunities for the region with major impact on the aforementioned regional ageing-related health issues. In summary, there is a clear need to design and valorize strategies to identify chronic age-related diseases at the earliest possible stage, to stratify patients for the most effective therapy (as current therapies are not effective in 70% of patients) and to slow-down the ageing process. Reliable biomarkers are crucial for each of these steps as are measures to slow down the aging process and harness the patient’s resilience to age-related diseases. In this program, experts from EMR academia with highly complementary expertises (University of Hasselt, MUMC, GIGA Liege, and UKA) and several private partners in health industry (Curador, MonaCell, Imec, GlycoCheck, Phacobel and ptTheragnostic), will synergize to tackle the expected epidemic of age-related chronic disorders by creating tools for: (1) early diagnosis for immune ageing and related chronic diseases (DIAGNOSIS), (2) personalized intervention in chronic diseases to improve response rate (“COMPOUND” DIAGNOSTICS), (3) new therapies, where current treatments fail (BETTER THERAPIES), (4) nutraceuticals to postpone ageing (and related diseases) (PREVENTION). Main activities and output: This project will screen established cohorts of elderly and chronically ill people for a set of biomarkers related to the immune system, metabolic status and bio-energetic status, as we consider these vital processes to be compromised in age-related chronic disorders. Especially immune aging is thought to predispose for illness at later age. We will capitalize on a range of up and running technology platforms, offering the project a true head-start. We will produce biomarkers that can indicate a patient’s “immune age”, predisposition to a specific chronic disease, and responsiveness and non-responsiveness to existing therapies. These biomarker sets will be deployed as companion diagnostics to monitor treatment efficacy in an individual, as well as to serve as surrogate endpoint in the efficacy screening of drugs and nutraceuticals (6) in a clinical setting. Furthermore, we will develop new (immuno)therapeutics and technology platforms for hand-on biomarker detection to further improve treatment success. Expected results: “Healthy ageing” will produce the following deliverables: Diagnostic measures to identify, Subjects with accelerated immune ageing, Chronic disease patients which are responsive to specific therapy, New therapeutics to treat non-responsive patients with age related chronic diseases, Nutraceuticals with potent immune-ageing reversing activity for preventive therapy, In conjunction with the associated private partners we will valorize these valuable assets to foster the product pipelines of the involved SME and launch new entrepreneurial activities targeting the ageing population. This results in acceleration of the valorisation chain, with deep socio-economical impact on the EMR region. Added value of the project: The tight collaboration of the different knowledge institutes across borders will create a synergistic hub of complementary expertises and give partners direct access to an unprecedented large set of cohorts of healthy subjects, as well as of patients with chronic ageing-related diseases (CVD, asthma, COPD, RA) and patients with neurodegeneration (MS). This setting is unique and allows for groundbreaking research in the field of ageing, immunity and chronic diseases. All studies will be based on the needs of and performed in close collaboration with Life Sciences companies in the Meuse-Rhine region to expedite the valorization of the new diagnostic and therapeutic tools. Hence this project will boost the region’s innovation and knowledge economy as a whole and will profile the Euregion as an expert hub for Healthy Ageing focused research and Biotech activties. (1) Broux B, Markovic-Plese S, Stinissen P, Hellings N. Pathogenic featu (English)
0 references